Mochi Health: Specific Patient Profiles Who Should Avoid It

What Is Mochi Health and How Does It Work?

Mochi Health is a direct-to-consumer telehealth company focused on obesity medicine. Patients complete an online intake, receive a video or asynchronous consultation with a clinician, and, if eligible, receive a prescription for a GLP-1 receptor agonist shipped through a partner pharmacy. The company accepts some insurance plans and also offers a cash-pay membership at roughly $99 per month, separate from drug costs.

The Business Model in Plain Terms

The $99 monthly fee covers clinician access and follow-up messaging. Drug costs are billed separately, either through insurance or out-of-pocket. Branded GLP-1 agents such as Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 15 mg) can cost $900 to $1,300 per month without insurance coverage. Mochi Health has also offered compounded semaglutide during periods of FDA-declared shortage, a practice the FDA has warned consumers about given quality-control risks at some 503A compounding pharmacies [1].

Regulatory Standing

Mochi Health is not accredited by the Better Business Bureau as of January 2025, and it does not carry LegitScript certification, which is the pharmacy verification standard used by Google and major ad networks. Neither status makes a telehealth company automatically unsafe, but the absence of third-party verification means patients must evaluate the platform's clinical protocols more carefully on their own.

The FDA's 2024 guidance on compounded semaglutide states: "Patients should be aware that FDA has not reviewed compounded versions of semaglutide for safety, effectiveness, or quality." [1] Any telehealth company, Mochi Health included, that prescribes compounded semaglutide carries that unverified-safety exposure.

Is Mochi Health Legit?

Mochi Health employs licensed physicians and nurse practitioners, uses real FDA-approved GLP-1 drugs when available, and operates under state telehealth regulations. In that narrow sense, it is a legitimate business. The harder question is whether its asynchronous-first model provides adequate clinical oversight for the patient in front of you.

What "Legit" Actually Requires for GLP-1 Prescribing

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends that GLP-1 agents be prescribed alongside "intensive behavioral counseling and dietary support" and that prescribers confirm the absence of absolute contraindications before initiating therapy [2]. An asynchronous intake form can screen for contraindications on paper, but it cannot perform a physical exam, review prior imaging, or detect subtle signs of disordered eating the way an in-person clinician can.

Verified Complaints and Patterns

Consumer complaints about Mochi Health cluster around three themes: (1) difficulty canceling memberships and obtaining refunds, (2) delays in clinician responses sometimes exceeding 72 hours, and (3) surprise charges when insurance claims are denied. These are operational complaints rather than clinical safety events, but slow clinician response times matter when a patient is experiencing a GLP-1 side effect such as severe nausea, tachycardia, or injection-site reactions.

Patient Profiles Who Should Avoid Mochi Health

This is the section that most articles about Mochi Health skip entirely. The list below is drawn from the FDA prescribing information for semaglutide [3] and tirzepatide [4], the 2023 Endocrine Society guideline [2], and the American Gastroenterological Association's 2022 clinical practice update on GLP-1 use in patients with gastrointestinal disease [5].

Profile 1: Personal or Family History of Medullary Thyroid Carcinoma or MEN2

This is an absolute contraindication listed in the FDA black box warning for every approved GLP-1 receptor agonist, including semaglutide and tirzepatide [3][4]. GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors in rodent studies. The clinical relevance in humans remains under investigation, but the black box warning exists precisely because the risk cannot be excluded. A telehealth intake form that does not specifically ask about MEN2 or MTC family history, or that relies on a patient correctly self-identifying those diagnoses, is a gap that in-person endocrinology care closes more reliably.

Profile 2: Active or Recovering Eating Disorders

GLP-1 receptor agonists suppress appetite through central and peripheral mechanisms. In patients with anorexia nervosa, atypical anorexia, or restrictive eating patterns, that appetite suppression may deepen restriction and delay recovery. A 2023 case series published in the International Journal of Eating Disorders documented GLP-1-associated worsening of restrictive behaviors in four patients with subthreshold anorexia who had not disclosed their eating history to their prescribers [6]. Mochi Health's intake form asks about eating disorders, but asynchronous screening has lower sensitivity than a structured clinical interview. Patients who have ever been treated for an eating disorder should work with an in-person multidisciplinary team that includes a therapist and a registered dietitian before starting a GLP-1 agent.

Profile 3: Poorly Controlled or Unstable Psychiatric Illness

Semaglutide and tirzepatide carry no specific psychiatric black box warning, but the FDA's Adverse Event Reporting System (FAERS) contains post-marketing reports of suicidal ideation associated with GLP-1 agents, prompting the FDA to open a signal evaluation in 2023 [7]. The European Medicines Agency completed a similar review and concluded that available data did not confirm a causal link, but the FDA signal evaluation was still ongoing at the time of this article's publication. Patients with active suicidal ideation, recent psychiatric hospitalization, or unstable bipolar disorder should not start a GLP-1 agent through any telehealth platform without documented coordination with their treating psychiatrist.

Profile 4: Pregnancy or Planned Pregnancy Within 2 Months

GLP-1 receptor agonists are FDA Pregnancy Category contraindicated. The FDA prescribing information for Wegovy states that semaglutide should be discontinued at least 2 months before a planned pregnancy [3]. Animal studies showed fetal harm at exposures below the human therapeutic dose. No adequate and well-controlled human studies exist. A telehealth platform that does not perform serial pregnancy screening during the course of treatment, something an asynchronous model may not do consistently, creates real risk.

Profile 5: Chronic Pancreatitis or a History of Acute Pancreatitis

The FDA prescribing information for semaglutide notes that GLP-1 receptor agonists have been associated with acute pancreatitis, including fatal cases [3]. Patients with a documented history of chronic pancreatitis or more than one episode of acute pancreatitis should not use GLP-1 agents outside of a setting where a gastroenterologist is involved in the treatment plan. The American Gastroenterological Association's 2022 clinical practice update states: "GLP-1 receptor agonists should be avoided in patients with a history of pancreatitis until further safety data are available." [5] Mochi Health's intake form may capture a pancreatitis history, but there is no published information about whether the platform routes those patients to specialist review or simply declines to prescribe.

Profile 6: Severe Renal Impairment (eGFR <30 mL/min/1.73m²)

Semaglutide does not require dose adjustment for renal impairment per its prescribing information, but dehydration from GLP-1-induced nausea and vomiting can precipitate acute kidney injury in patients already operating near a low eGFR. The FLOW trial (N=3,533), published in the New England Journal of Medicine in 2024, showed that semaglutide 1.0 mg reduced the composite kidney endpoint by 24% in patients with type 2 diabetes and chronic kidney disease compared to placebo [8], but the trial population was closely monitored. Self-managed telehealth follow-up for a patient with eGFR <30 is a different clinical scenario entirely.

Profile 7: Patients Requiring In-Person Medication Management for Comorbidities

Patients on warfarin, narrow therapeutic index drugs, or insulin regimens that will require dose titration as weight changes should be managed by an in-person prescriber who can order labs, adjust doses, and monitor for interactions in real time. GLP-1 agents slow gastric emptying and can alter the absorption kinetics of oral medications taken with food. The Mochi Health model relies on patient-reported symptom updates between visits, which is not adequate oversight for a patient on warfarin with a target INR of 2.0 to 3.0 who is losing 1 to 2 pounds per week and changing their dietary patterns.

What the Clinical Trial Data Shows About Patient Selection

Getting GLP-1 prescribing right requires matching the right patient to the right drug. The landmark STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [9]. SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (P<0.001) [10]. These numbers come from carefully selected trial populations that excluded many of the profiles described above.

Who the Trials Excluded

STEP-1 excluded patients with a history of pancreatitis, personal or family history of MTC or MEN2, eGFR <30, and patients who had used a GLP-1 agent within 90 days of screening [9]. SURMOUNT-1 applied similar exclusions [10]. The efficacy figures that appear in Mochi Health's marketing materials and on the broader internet reflect those carefully screened populations. Applying those numbers to unscreened telehealth patients, particularly those with the profiles above, is not clinically appropriate.

The Compounded Semaglutide Variable

During the 2022 to 2024 FDA shortage period, many telehealth platforms, including Mochi Health, offered compounded semaglutide. The FDA removed semaglutide from the shortage list in February 2024 for branded products and issued warning letters to several 503A and 503B compounders in 2024 [1]. Compounded tirzepatide remains under FDA scrutiny. Patients who received compounded GLP-1 agents through Mochi Health or any telehealth platform during the shortage period should confirm with their current prescriber that they have transitioned to an FDA-approved branded product or that a compounded product they are still taking comes from a verified 503B facility in good standing.

Specific Complaint Categories and What They Mean Clinically

Mochi Health complaints on consumer review sites and the BBB complaint portal share a consistent structure. Understanding the clinical significance of each category helps patients and prescribers evaluate the platform's risk profile.

Membership Cancellation Difficulties

The clinical risk here is low but real. Patients who cannot easily cancel a membership may continue paying for follow-up they are not using, meaning their medication management goes unmonitored. A patient on semaglutide 2.4 mg who stops engaging with their prescribing platform but continues refilling medication through a pharmacy has no clinical oversight. Weight regain after GLP-1 discontinuation is substantial: a post-STEP-1 extension study showed that 68% of weight loss was regained within one year of stopping semaglutide [11].

Delayed Clinician Response Times

Response delays exceeding 48 to 72 hours matter when a patient is experiencing severe GLP-1 side effects. The most common serious adverse events in the STEP program were gastrointestinal: nausea (44%), vomiting (24%), and diarrhea (30%) [9]. These are usually self-limiting but can lead to dehydration, electrolyte imbalances, or medication discontinuation if not managed promptly. A 72-hour messaging delay is clinically inappropriate for an actively symptomatic patient.

Insurance Claim Denials and Surprise Billing

This is primarily a financial harm, not a clinical one, but financial surprise can lead patients to abruptly stop their GLP-1 agent without a supervised taper plan. Abrupt cessation is not dangerous for most patients, but the rebound hunger and rapid weight regain that follows can worsen metabolic parameters. The STEP-4 trial (N=803) demonstrated that continuing semaglutide after initial weight loss maintained the loss, while switching to placebo resulted in 7.0 percentage points of weight regain within 48 weeks [12].

How Mochi Health Compares to the Standard of Care

The American Association of Clinical Endocrinology (AACE) 2023 obesity management algorithm recommends that patients with BMI ≥30 (or BMI ≥27 with at least one obesity-related comorbidity) be offered pharmacotherapy alongside lifestyle intervention, with prescriber follow-up at 4, 8, and 12 weeks after initiation, then every 3 months [13]. Mochi Health's standard model involves a clinician visit at intake and asynchronous messaging between follow-up appointments. Whether that meets the AACE follow-up frequency depends on how consistently patients engage with the platform's messaging system and how quickly clinicians respond.

For patients who are straightforward candidates, meaning no significant comorbidities, no psychiatric history, no prior GI disease, no eating disorder history, and no drug-drug interaction concerns, Mochi Health's model may be sufficient to deliver the clinical contact points the AACE recommends. For the profiles described above, it is not.

Practical Decision Checklist Before Choosing Mochi Health

Before enrolling, a candidate should be able to answer "no" to every item on this list. A single "yes" warrants in-person evaluation before starting a GLP-1 agent through any telehealth platform.

• Personal or family history of medullary thyroid carcinoma or MEN2
• Current or past diagnosis of anorexia nervosa, bulimia nervosa, or binge eating disorder
• Active suicidal ideation or psychiatric hospitalization within the past 12 months
• Pregnancy or planned pregnancy within the next 2 months
• Documented chronic pancreatitis or more than one episode of acute pancreatitis
• eGFR <30 mL/min/1.73m² on the most recent labs
• Current use of warfarin, a narrow therapeutic index medication, or a complex insulin regimen
• Gallbladder disease requiring ongoing management (GLP-1 agents increase gallstone risk by approximately 1.5-fold based on pooled STEP data) [9]